Eyepoint Pharmaceuticals (EYPT) Releases Earnings Results, Misses Expectations By $0.08 EPS
Eyepoint Pharmaceuticals (NASDAQ:EYPT) announced its quarterly earnings results on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.08), Fidelity Earnings reports. The firm had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $0.67 million. Eyepoint Pharmaceuticals had a negative net margin of 843.54% and a negative return on equity of 246.01%.
NASDAQ:EYPT traded down $0.09 during mid-day trading on Thursday, hitting $2.19. The company’s stock had a trading volume of 107,375 shares, compared to its average volume of 240,755. Eyepoint Pharmaceuticals has a 1 year low of $0.93 and a 1 year high of $2.88. The company has a debt-to-equity ratio of 1.57, a quick ratio of 0.83 and a current ratio of 0.83. The firm has a market cap of $123.73 million, a price-to-earnings ratio of -4.21 and a beta of 0.97.
EYPT has been the subject of a number of research reports. HC Wainwright set a $3.00 price target on Eyepoint Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 2nd. Zacks Investment Research raised shares of Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 28th. Finally, ValuEngine raised Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 29th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $4.85.
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.